"2025年上半年度，公司销售渠道优化与产品价格梳理工作取得阶段性进展，销售渠道逐渐回归健康， 产品价格梳理工作已阶段性完成。公司2025年第二季度营业收入环比第一季度增长86.68%，业绩出现 回暖，进展符合公司预期。"敷尔佳向机构投资者介绍，销售渠道优化与产品价格梳理是持续、动态开 展的，销售渠道优化主要是针对线下经销渠道，未来随着线下经销商合规运营，公司期待线下销售渠道 能有更好的表现。 敷尔佳表示，从公司销售数据看，今年6·18期间抖音和天猫都呈增长态势，增长情况比较乐观，线上整 体销售情况都符合预期。今年上半年度，京东平台的增速比较亮眼，主要是公司在上半年加深了与京东 之间的合作，丰富了京东平台的产品种类，增加了一些新的合作方式，例如：满赠活动、新品首发等， 双方紧密合作，共同努力，实现了京东平台的快速增长。上半年度抖音达播占比有所收紧，主要是公司 开展销售渠道优化与产品价格梳理，收缩了部分高费比渠道，目前达播主要集中在大促期间，日常也有 但不多。 据介绍，敷尔佳线下主要是经销模式，经销收入占比超过99%，线下基本没有销售费用，主要是销售人 员工资和一些线下活动的物料费用。 相较于去年同期，公司非贴 ...

Core Viewpoint - The ongoing tariff policies from the U.S. are increasing economic uncertainty and negatively impacting the global pharmaceutical market, prompting Chinese pharmaceutical companies to seek ways to navigate these challenges [1][2]. Group 1: Impact on Chinese Pharmaceutical Industry - In 2024, China's total pharmaceutical import and export volume is projected to reach $199.38 billion, a year-on-year increase of 2.1%, with exports amounting to $107.96 billion, up 5.9%, marking the end of a two-year decline [1]. - The export of traditional Chinese medicine products decreased by 3.3% to $5.28 billion, while exports of Western medicine products increased by 5.7% to $53.96 billion, and medical device exports rose by 7.3% to $48.75 billion [1]. - Chinese pharmaceutical companies primarily focus on the domestic market, with limited export scale to the U.S., and the short-term impact of U.S. tariff policies is expected to be minimal due to temporary exemptions [4]. Group 2: U.S. Pharmaceutical Market Challenges - The U.S. pharmaceutical market is facing significant challenges, with a 25% tariff potentially increasing annual drug costs by $51 billion and raising drug prices by up to 12.9% if costs are fully passed on [3]. - The U.S. is experiencing shortages of hundreds of drugs, including critical emergency medications, due to various factors such as increased prescription volumes and manufacturing delays [3]. - The U.S. heavily relies on imports for 80% of its active pharmaceutical ingredients, making it vulnerable to tariff impacts that could disrupt its medical supply chain [2][3]. Group 3: Strategic Recommendations for Chinese Pharmaceutical Companies - Chinese pharmaceutical companies are advised to enhance their independent research and innovation capabilities to maintain competitiveness amid uncertainties [6]. - Companies should optimize their global presence, focusing on stabilizing markets in Europe and the U.S. while also exploring emerging markets [6]. - There is a need to improve product structures and tap into domestic market growth opportunities, such as those arising from the aging population [6].

正式报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月26日， 奥美医疗 发布了2024年年报。 | | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 3,326,292,089.93 | 2,756,665,325.19 | 20.66% | 4,210,502,651.18 | | 归属于上市公司股东的净利润(元) | 368,679,147.09 | 110,399,864.30 | 233.95% | 406,791,688.71 | | 归属于上市公司股东的扣除非经常性损益的净利 润(元) | 343,356,546.28 | 154,465,339.81 | 122.29% | 612,003,578.87 | | 经营活动产生的现金流量净额(元) | 711,644,736.40 | 423,504,615.05 | 68.04% | 1,149,727,552.87 | | 基本每股收益(元/股) | 0.5899 | 0.1743 ...